The Department of Commerce appears to have concluded its Section 232 investigation into pharmaceutical imports, according to a new document reviewed by Endpoints News, Anna Brown reports. Publicly traded companies in the space include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- J&J announces new longer follow-up results from Phase 1b/2 OrigAMI-1 study
- Johnson & Johnson Wins Tariff Relief from Trump in a Drug Pricing Deal
- Trump Weekly: President blasts institutional home buying, Defense buybacks
- Midday Fly By: Job growth comes in below forecasts in December
- Trump Trade: Intel rises after President touts ‘great meeting’ with CEO